Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

ClinicalTrials.gov ID: NCT00228969

Public ClinicalTrials.gov record NCT00228969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive

Study identification

NCT ID: NCT00228969
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: SK Life Science, Inc.; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Refractory Epilepsy

Interventions

RWJ-333369 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 79 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2005 (Type not available)
Primary completion: May 2006 (Actual)
Completion: May 2006 (Actual)
Last update posted: Aug 2, 2012

2005 – 2006

United States locations

U.S. sites: 29
U.S. states: 19
U.S. cities: 29

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	—	—
Not listed	Huntsville	Alabama	—	—
Not listed	Mobile	Alabama	—	—
Not listed	Northport	Alabama	—	—
Not listed	Phoenix	Arizona	—	—
Not listed	Little Rock	Arkansas	—	—
Not listed	Irvine	California	—	—
Not listed	Northridge	California	—	—
Not listed	Sacramento	California	—	—
Not listed	Fort Collins	Colorado	—	—
Not listed	Wilmington	Delaware	—	—
Not listed	Decatur	Georgia	—	—
Not listed	Lexington	Kentucky	—	—
Not listed	Louisville	Kentucky	—	—
Not listed	Baton Rouge	Louisiana	—	—
Not listed	Golden Valley	Minnesota	—	—
Not listed	Saint Paul	Minnesota	—	—
Not listed	Chesterfield	Missouri	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	Portland	Oregon	—	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Sellersville	Pennsylvania	—	—
Not listed	Nashville	Tennessee	—	—
Not listed	Dallas	Texas	—	—
Not listed	El Paso	Texas	—	—
Not listed	Bennington	Vermont	—	—
Not listed	Charlottesville	Virginia	—	—
Not listed	Roanoke	Virginia	—	—
Not listed	Madison	Wisconsin	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00228969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 2, 2012 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00228969 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →